CompletedPhase 1NCT01842386

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

Studying NON RARE IN EUROPE: Idiopathic cutaneous and mucosal candidosis

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Christa S Zerbe, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Intervention: Rituximab(drug)
Enrollment: 7 enrolled
Eligibility: 18-99 years · All sexes
Timeline: 2014 – 2021

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01842386 on ClinicalTrials.gov

← Back to all trials